Sector Expert: Juan Sanchez

Ladenburg Thalmann

Dr. Juan F. Sanchez is a vice president at Ladenburg Thalmann & Co. Inc, Research Division. He covers biotechnology and nanotechnology sectors with a focus on central nervous system therapeutics. Dr. Sanchez's previous experience includes oncology marketing at Bristol Myers Squibb and post-genomic strategy planning at the Office of the Vice Provost, Columbia University. He has five years of experience in clinical medical practice. Dr. Sanchez received a Master in International Affairs from Columbia University, a Master of Business Administration from University of Los Andes and a Medical Doctor degree from Javeriana University.



Recent Quotes

"We believe the ADX71149 program could be potentially transformative for ADXN."

— Juan Sanchez, Ladenburg Thalmann (2/8/13)
more >

"ADXN has two assets addressing real medical needs in midstage clinical development."

— Juan Sanchez, Ladenburg Thalmann (11/5/12)
more >

"We reiterate our Buy rating on ADXN."

— Juan Sanchez, Ladenburg Thalmann (8/29/12)
more >

"We reiterate our Buy rating on ADXN."

— Juan Sanchez, Ladenburg Thalmann (8/22/12)
more >

"Data show ADXN's dipraglurant is safe and active (in treating LID)."

— Juan Sanchez, Ladenburg Thalmann (6/21/12)
more >

"Positive data from a phase 2 study of ADX71149 could be transformative for ADXN."

— Juan Sanchez, Ladenburg Thalmann (6/5/12)
more >

"New findings highlight dipraglurant's potential positioning; ADXN is a Buy."

— Juan Sanchez, Ladenburg Thalmann (12/6/11)
more >

"ADXN is advancing its internal pipeline, generating important partnerships."

— Juan Sanchez, Ladenburg Thalmann (8/16/11)
more >



Due to permission requirements, not all quotes are shown.